摘要
目的探讨卡培他滨联合多西紫杉醇一线治疗晚期胃癌的近期疗效、不良反应及生存情况。方法 2010年1月至2012年7月共24例晚期胃癌患者采用卡培他滨联合多西紫杉醇一线化疗,具体方案为:卡培他滨1000mg/m2口服,每天2次,d1～d14;多西紫杉醇75mg/m2静滴1h,d1,或者多西紫杉醇35mg/m2静滴1h,d1、d8。21天为1周期,至少化疗2个周期。2个周期评价疗效,每周期评价不良反应。结果 24例患者均可评价疗效。无CR病例,获PR 3例,SD 20例,PD 1例;有效率为12.5%,疾病控制率为95.8%。中位总生存时间为10.5个月(95%CI:2.47～18.47个月);10例患者死于疾病进展,其中7例的疾病进展时间为1.7～15.2个月。主要不良反应为骨髓抑制和手足综合征,以1～2级为主,全组患者无治疗相关性死亡。结论卡培他滨联合多西紫杉醇一线治疗晚期胃癌的疗效确切,不良反应可耐受,值得深入研究。
Objective To evaluate the efficacy, side effects and survival of capecitabine plus docetaxel for the first-line treat- ment of advanced gastric cancer. Methods From January 2010 to July 2012, 24 cases of advanced gastric cancer were enrolled to re- ceive capecitabine plus doeetaxel regimen. Treatment consisted of 3-week cycles of twice-daily eapecitabin 1000mg/m2 （on days 1-14） and intravenous docetaxel 75mg/mz lh, dlOr 35mg/m21h, d1 , d8. Each patient received at least 2 cycles. The efficacy was evaluated every two cycles and side effects were evaluated each cycle. Results The efficacy could be evaluated in 24 patients, none of them a- chieved complete responses, 3 showed partial responses, 20 had stable disease, and 1 got progressive disease. The response rate was 12.5% and the disease control rate was 95.8%. The median overall survival was 10. 5 months（95% CI： 2.47-18.47months）. Ten patients died fi＇om disease progression, and the time to progression of 7 patients was 1.7-15.2months. The main side effects were my- elosuppression and hand-foot syndrome, mainly in grade 1-2, and none of them suffered treatment related death. Conclusion Capeeitabine plus docetaxel regimen for the first-line treatment of advanced gastric cancer has a definite effect with acceptable toxicity, which is worth further study.
出处
《临床肿瘤学杂志》
CAS
2013年第5期442-444,共3页
Chinese Clinical Oncology
基金
辽宁省国家创新药物孵化基地建设资助项目(2010ZX09401-304-110G)
关键词
晚期胃癌
卡培他滨
多西紫杉醇
Advanced gastric cancer
Capecitabine
Docetaxel
